Combination Treatments in Borderline Personality Disorder: Bridging the Gap Between Clinical Practice and Empirical Data
- 39 Downloads
Purpose of Review This paper presents an empirical basis for combination treatments in borderline personality disorder (PD), including medication combinations, psychotherapy combinations, and psychotherapy with medication. The goals are to synthesize empirical data evaluating combination treatments and to demonstrate gaps between research and clinical practice.
Recent Findings The limited research supporting combination treatments displayed mixed results. There is minimal support for the frequent clinical practice of polypharmacy, with some evidence for the use of atypical antipsychotics with antidepressants. The scant research in combination psychotherapies supported its use primarily in individuals with comorbid psychiatric disorders (e.g., borderline PD and PTSD). Similarly, medication combined with psychotherapy had the greatest utility in individuals with comorbid psychiatric diagnoses.
Summary Further research is needed before firm conclusions can be drawn on the use of combination treatments in borderline PD. The few studies that exist had mixed results, were often based on small sample sizes, and had abbreviated treatment courses. Nonetheless, there does appear to be a potential utility in the use of combination treatments for this complex neuropsychiatric disorder with significant morbidity and mortality, a wide range of symptoms, and frequent comorbid diagnoses.
KeywordsBorderline personality disorder Combination treatments Combination medications Combination psychotherapy Medication with psychotherapy Polypharmacy
Compliance with ethical standards
Conflict of interest
Lea K. Marin declares that she has no conflict of interest. Rachel E. Harris declares that she has no conflict of interest. Kalpana N. Kapil-Pair declares that she has no conflict of interest. Marianne Goodman serves as a consultant for Boehringer Ingleheim Pharmaceuticals.
Human and animal rights and informed consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 1.APA. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Association; 2013.Google Scholar
- 3.Oldham J, Gabbard G, Goin M, et al. (2001) Practice guideline for the treatment of patients with borderline personality disorder. APA practice guidelines for the treatment of psychiatric disorders: comprehensive guidelines and guideline watches. doi: https://doi.org/10.1176/appi.books.9780890423363.54853.
- 4.• Bridler R, Häberle A, Müller ST, et al. Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: a comparison with other psychiatric disorders. Eur Neuropsychopharmacol. 2015;25(6):763–72. https://doi.org/10.1016/j.euroneuro.2015.03.017. This study identifies prescribing data to show widespread use of polypharmacy in borderline PD treatment.
- 7.Stoffers JM, Völlm BA, Rücker G, et al. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev. 2012;8:CD005652.Google Scholar
- 10.Podobnik J, Foller Podobnik I, Grgic N, et al. The effect of add-on treatment with quetiapine on measures of depression, aggression, irritability and suicidal tendencies in children and adolescents. Psychopharmacology. 2012;220(3):639–41. https://doi.org/10.1007/s00213-011-2607-7.CrossRefPubMedGoogle Scholar
- 14.• Bellino S, Bozzatello P, Bogetto F. Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Res. 2015;226(1):284–8. https://doi.org/10.1016/j.psychres.2014.12.064. This research provides evidence that certain clinical predictors of combined treatment response could potentially impact severity of borderline PD symptoms.
- 18.Prada P, Nicastro R, Zimmermann J, et al. Addition of methylphenidate to intensive dialectical behaviour therapy for patients suffering from comorbid borderline personality disorder and ADHD: a naturalistic study. Atten Defic Hyperact Disord. 2015;7(3):199–209. https://doi.org/10.1007/s12402-015-0165-2.CrossRefPubMedGoogle Scholar
- 22.• Antonsen BT, Kvarstein EH, Urnes Ø, Hummelen B, et al. Favourable outcome of long-term combined psychotherapy for patients with borderline personality disorder: Six-year follow-up of a randomized study. Psychother Res. 2017;27(1):51–63. This study provides a discussion of how combined psychotherapies may lead to diagnostic remission, greater symptom reduction, and improvement in the identity integration and self-control domains for patients with borderline PD>. Google Scholar
- 23.Edel MA, Raaff V, Dimaggio G, et al. Exploring the effectiveness of combined mentalization-based group therapy and dialectical behaviour therapy for inpatients with borderline personality disorder—a pilot study. Br J Clin Psychol. 2017;56(1):1–15. https://doi.org/10.1111/bjc.12123.CrossRefPubMedGoogle Scholar
- 24.• Harned MS, Korslund KE, Linehan MM. A pilot randomized controlled trial of dialectical behavior therapy with and without the dialectical behavior Therapy Prolonged Exposure protocol for suicidal and self-injuring women with borderline personality disorder and PTSD. Behav Res Ther. 2014;55:7–17. https://doi.org/10.1016/j.brat.2014.01.008. This study discussed how combined DBT-PE achieved diagnostic remission, symptom reduction, and improvements in the emotional and cognitive constructs.
- 25.Marcinko D, Bilic V. Family therapy as addition to individual therapy and psychopharmacotherapy in late adolescent female patients suffering from borderline personality disorder with comorbidity and positive suicidal history. Psychiatr Danaub. 2010;22(2):257–60.Google Scholar
- 26.• Stoffers JM, Lieb K. Pharmacotherapy for borderline personality disorder--current evidence and recent trends. Curr Psychiatry Rep. 2015;17:534. https://doi.org/10.1007/s11920-014-0534-0. Authors provide an overview of the most current treatments and identify trends in ongoing trials.